PIL- Terbinafine 250mg Tablets: Change history
View Patient Information Leaflet (PIL- Terbinafine 250mg Tablets)
Last updated on this site: 30 Sep 2026
SmPC sections 4.4, 4.8, and PIL sections 2, 4 have been updated in line with PSUSA/00002896/202509 for thrombotic thrombocytopaenic purpura. Additionally, a heading has been added to the sodium excipient warning in SmPC section 4.4.
Date of approval: 28/09/2026
PIL sections updated: 2, 4 and 6
Last updated on this site: 30 Sep 2026
SmPC sections 4.4, 4.8, and PIL sections 2, 4 have been updated in line with PSUSA/00002896/202509 for thrombotic thrombocytopaenic purpura. Additionally, a heading has been added to the sodium excipient warning in SmPC section 4.4.
Date of approval: 28/09/2026
PIL sections updated: 2, 4 and 6
-
Changes: (Updated: 30 Sep 2026)
SmPC sections 4.4, 4.8, and PIL sections 2, 4 have been updated in line with PSUSA/00002896/202509 for thrombotic thrombocytopaenic purpura. Additionally, a heading has been added to the sodium excipient warning in SmPC section 4.4.
Date of approval: 28/09/2026
PIL sections updated: 2, 4 and 6
-
Changes: (Updated: 27 Apr 2023)
Variation Description: To update SmPC section 4.4 in line with the EC guidelines on Excipients (EMA/CHMP/302620/2017) for sodium and QRD template, consequently section 2 of the PIL has been updated. Section 4 of the PIL has also been updated to remove duplicate side effects following request from the MHRA in grant letter MHRA ref: PL 00142/0628 – 0059, dated 09/10/2019. We have also taken this opportunity to move serious side effects under the correct frequency in line with SmPC section 4.8.
PIL sections updated – Heading, 2, 3, 4, 5 and 6.
-
Changes: (Updated: 22 Sep 2022)
initial upload